Welcome
Support Centre
11 February 2012 
Current Controlled Trials - Clinical Trials
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Introduction
English introduction Introduction en français Deutsche einleitung
Introducción española Introduzione in italiano
 
Find trials
active registers
mental health register
archived registers
all registers
tips on searching
 
 
Information
about mRCT
mRCT FAQs

DISCLAIMER
The site should not be used to diagnose or treat a health problem. Please consult your doctor.
Terms & conditions

DUPLICATION
Your search result may contain a number of different records for the same trial. This occurs when the same trial is listed in more than one register.

[ ...Back to search results ] [ Print-friendly version ]
A multi-centred randomised study of parotid sparing intensity modulated radiotherapy (IMRT) to reduce xerostomia and increase quality of life in head and neck cancer
Source of recordUK Trials
ISRCTNISRCTN48243537
Date ISRCTN assigned15/10/2002
Local reference number(s)Parotid Sparing IMRT
Public titleA multi-centred randomised study of parotid sparing intensity modulated radiotherapy (IMRT) to reduce xerostomia and increase quality of life in head and neck cancer
Scientific title
AcronymN/A
Disease/condition/study domainHead and Neck
Study hypothesisNot provided at time of registration.
Design/methodologyRandomised controlled trial
Research ethics reviewNot provided at time of registration.
Countries of trialUnited Kingdom
Participants - inclusion criteria1. Histologically confirmed squamous cell or undifferentiated carcinoma of the head and neck
2. Tumour arising from the oro-pharynx requiring radical radiation of the primary tumour by parallel opposed lateral fields and bilateral cervical lymph node irradiation. High risk of radiation induced xerostomia with conventional radiotherapy due to irradiation of the majority of both parotid glands. Radiotherapy either as the primary treatment or post-operative (adjuvant irradiation). Neoadjuvant chemotherapy is permitted.
3. All patients must be suitable to attend regular follow-up and undergo QoL and salivary measurements. Stage T1-4, N1-3, M0 disease. Zubrod performance status 0-1.
Participants - exclusion criteriaNot provided at time of registration.
Patient information material
Anticipated start date01/10/2001
Anticipated end date01/10/2006
Status of trialCompleted
Target number of participantsNot provided at time of registration.
InterventionsPatients are randomised to receive either conventional radiotherapy or parotid-sparing IMRT
Primary outcome measure(s)Not provided at time of registration.
Secondary outcome measure(s)Not provided at time of registration.
Sources of fundingInstitute of Cancer Research
Sponsor nameThe Institute of Cancer Research (UK)
Sponsor details123 Old Brompton Road
London
United Kingdom
SW7 3RP
Sponsor telephone+44(0) 20 7352 8133
Sponsor fax+44(0) 20 7370 5261
Sponsor emailsponsor@unknown.com
Sponsor websitehttp://www.icr.ac.uk
Contact nameDr - -
Contact detailsUKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA
Contact telephone+44 (0) 20 7670 4723
Contact fax+44 (0) 20 7670 4818
Contact emailregister@ctu.mrc.ac.uk
More informationFor more up-to-date information please go to the ISRCTN link below.
Link to record in ISRCTN RegisterISRCTN48243537
Date last extracted from ISRCTN register17/04/2008
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 Current Controlled Trials Ltd. Part of Springer Science+Business Media. | terms & conditions | privacy statement


BioMed Central